tetano
Editor, Senior Moderator
Viruses
. 2020 Oct 31;12(11):E1246.
doi: 10.3390/v12111246.
A Mutated PB1 Residue 319 Synergizes with the PB2 N265S Mutation of the Live Attenuated Influenza Vaccine to Convey Temperature Sensitivity
Andrew Cox[SUP] 1 2 3 [/SUP], Jordana Schmierer[SUP] 1 [/SUP], Josephine D'Angelo[SUP] 1 4 [/SUP], Andrew Smith[SUP] 1 2 [/SUP], Dustyn Levenson[SUP] 1 5 [/SUP], John Treanor[SUP] 1 6 7 [/SUP], Baek Kim[SUP] 1 8 9 [/SUP], Stephen Dewhurst[SUP] 1 [/SUP]
Affiliations
Abstract
Current influenza vaccines have modest efficacy. This is especially true for current live attenuated influenza vaccines (LAIV), which have been inferior to the inactivated versions in recent years. Therefore, a new generation of live vaccines may be needed. We previously showed that a mutation at PB1 residue 319 confers enhanced temperature sensitivity and attenuation in an LAIV constructed in the genetic background of the mouse-adapted Influenza A Virus (IAV) strain A/PR/8/34 (PR8). Here, we describe the origin/discovery of this unique mutation and demonstrate that, when combined with the PB2 N265S mutation of LAIV, it conveys an even greater level of temperature sensitivity and attenuation on PR8 than the complete set of attenuating mutations from LAIV. Furthermore, we show that the combined PB1 L319Q and PB2 N265S mutations confer temperature sensitivity on IAV polymerase activity in two different genetic backgrounds, PR8 and A/Cal/04/09. Collectively, these findings show that the PB2 LAIV mutation synergizes with a mutation in PB1 and may have potential utility for improving LAIVs.
Keywords: Influenza A Virus; LAIV; polymerase; temperature sensitivity; vaccine.
. 2020 Oct 31;12(11):E1246.
doi: 10.3390/v12111246.
A Mutated PB1 Residue 319 Synergizes with the PB2 N265S Mutation of the Live Attenuated Influenza Vaccine to Convey Temperature Sensitivity
Andrew Cox[SUP] 1 2 3 [/SUP], Jordana Schmierer[SUP] 1 [/SUP], Josephine D'Angelo[SUP] 1 4 [/SUP], Andrew Smith[SUP] 1 2 [/SUP], Dustyn Levenson[SUP] 1 5 [/SUP], John Treanor[SUP] 1 6 7 [/SUP], Baek Kim[SUP] 1 8 9 [/SUP], Stephen Dewhurst[SUP] 1 [/SUP]
Affiliations
- PMID: 33142846
- DOI: 10.3390/v12111246
Abstract
Current influenza vaccines have modest efficacy. This is especially true for current live attenuated influenza vaccines (LAIV), which have been inferior to the inactivated versions in recent years. Therefore, a new generation of live vaccines may be needed. We previously showed that a mutation at PB1 residue 319 confers enhanced temperature sensitivity and attenuation in an LAIV constructed in the genetic background of the mouse-adapted Influenza A Virus (IAV) strain A/PR/8/34 (PR8). Here, we describe the origin/discovery of this unique mutation and demonstrate that, when combined with the PB2 N265S mutation of LAIV, it conveys an even greater level of temperature sensitivity and attenuation on PR8 than the complete set of attenuating mutations from LAIV. Furthermore, we show that the combined PB1 L319Q and PB2 N265S mutations confer temperature sensitivity on IAV polymerase activity in two different genetic backgrounds, PR8 and A/Cal/04/09. Collectively, these findings show that the PB2 LAIV mutation synergizes with a mutation in PB1 and may have potential utility for improving LAIVs.
Keywords: Influenza A Virus; LAIV; polymerase; temperature sensitivity; vaccine.